Sponsors (78)
The bill directs multi‑year federal attention and funding to uterine fibroids—aiming to improve research, targeted outreach, and patient information (especially for minority and publicly insured women)—but does so at measurable taxpayer cost, with risks of administrative burden, resource diversion from other health priorities, and potential unintended limits or unevenness in outreach and treatment choices.
Women with uterine fibroids (especially reproductive‑age and symptomatic patients) stand to gain from increased federal research and attention leading to improved diagnostics, fertility‑preserving and minimally invasive treatments, and better clinical care.
Researchers, clinics, and health programs receive multi‑year federal support (research funding and authorized outreach funds for 2026–2030), creating stable resources for studies, clinical trials, and sustained public education efforts.
Medicaid/CHIP beneficiaries and state policymakers will get better data on fibroid treatment frequency and spending, enabling more informed coverage and budget decisions for low‑income and publicly insured patients.
Taxpayers face increased federal spending (including an explicit $150 million research cost over five years plus additional authorized outreach spending), raising budgetary pressure and potential tradeoffs with other priorities.
Targeting funds to fibroid research and programs risks diverting limited NIH/AHRQ resources away from other diseases and research priorities if overall budgets are constrained.
States, Medicaid/CHIP administrators, and health providers may incur additional administrative and reporting burdens to collect data, implement outreach, and adopt guideline materials, raising costs and workload.
Based on analysis of 7 sections of legislative text.
Authorizes federal research funding, Medicaid/CHIP data collection, public education, and evidence‑based care promotion for uterine fibroids, with targeted outreach to minority populations.
Official title: To provide for research and education with respect to uterine fibroids, and for other purposes.
Introduced July 15, 2025 by Yvette Diane Clarke · Last progress July 15, 2025
Directs the Department of Health and Human Services to expand and coordinate research, collect Medicaid/CHIP data, run public education, and promote evidence-based care related to uterine fibroids. It authorizes $30 million per year (FY2026–2030) for research and provides additional unspecified funding for education and care-promotion activities. Requires creation or expansion of a research database for Medicaid and CHIP services for fibroid treatment and a Congress report on federal and state expenditures within two years; mandates outreach focused on minority populations at higher risk and dissemination of non‑hysterectomy treatment information.